Endogenous subclinical hyperthyroidism: who, when and why to treat

References

• Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr. Rev.29(1), 76–131 (2008).
   PubMed Web of Science ®Google Scholar
• Wartofsly L. Management of subclinical hyperthyroidism. J. Clin. Endocrinol. Metab.96(1), 59–61 (2011).
   PubMedGoogle Scholar
• Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat. Clin. Pract. Endocrinol. Metab.1(1), 32–40 (2005).
   PubMedGoogle Scholar
• Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid20(2), 135–146 (2010).
   PubMed Web of Science ®Google Scholar
• Biondi B, Kahaly G. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat. Rev. Endocrinol.6(8), 431–443 (2010).
   PubMed Web of Science ®Google Scholar
• Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med.137, 904–914 (2002).
   PubMed Web of Science ®Google Scholar
• Ladenson PW. Thyrotoxicosis and the heart: something old and something new. J. Clin. Endocrinol. Metab.77(2), 332–333 (1993).
   PubMedGoogle Scholar
• Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur. J. Endocrinol.152, 1–9 (2005).
   PubMed Web of Science ®Google Scholar
• Mitchell AL, Pearce SH. How should we treat patients with low serum thyrotropin concentrations? Clin. Endocrinol.72, 292–296 (2010).
   PubMed Web of Science ®Google Scholar
• Laurberg P, Cerqueira C, Ovesen L et al. Iodine intake as a determinant of thyroid disorders in populations. Best Pract. Res. Clin. Endocrinol. Metab.24(1), 13–27 (2010).
   PubMed Web of Science ®Google Scholar
• Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J. Clin. Endocrinol. Metab.83, 765–769 (1998).
   PubMed Web of Science ®Google Scholar
• Biondi B, Palmieri E A, Filetti S, Lombardi G, Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. Lancet359(9308), 799–800 (2002).
   PubMedGoogle Scholar
• Biondi B. Cardiovascular mortality in subclinical hyperthyroidism: an ongoing dilemma. Eur. J. Endocrinol.162(3), 587–589 (2010).
   PubMedGoogle Scholar
• Bauer DC, Ettinger B, Nevitt MC, Stone KL. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med.134, 561–568 (2001).
   PubMed Web of Science ®Google Scholar
• Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM. Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study. Eur. J. Endocrinol.164(1), 107–113 (2011).
   PubMed Web of Science ®Google Scholar
• Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin. Endocrinol.68, 491–492 (2008).
   PubMedGoogle Scholar
• Woeber KA. Observations concerning the natural history of subclinical hyperthyroidism. Thyroid15(7), 687–691 (2005).
   PubMed Web of Science ®Google Scholar
• Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): The Natural History of Endogenous Subclinical Hyperthyroidism. J. Clin. Endocrinol. Metab.96(1), 1–8 (2011).
   PubMed Web of Science ®Google Scholar
• Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin. Endocrinol.72, 685–688 (2010).
   PubMed Web of Science ®Google Scholar
• Schouten BJ, Brownlie BEW, Frampton CM, Turner JG. Subclinical thyrotoxicosis in an outpatient population-predictors of outcome. Clin. Endocrinol.74(2), 257–261 (2011).
   PubMed Web of Science ®Google Scholar
• Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog. Horm. Res.59, 31–50 (2004).
   PubMedGoogle Scholar
• Biondi B, Palmieri EA, Fazio S et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J. Clin. Endocrinol. Metab.85, 4701–4705 (2003).
   Google Scholar
• Sgarbi JA, Villaca F, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. J. Clin. Endocrinol. Metab.88, 1672–1677 (2003).
   PubMed Web of Science ®Google Scholar
• Kaminski G, Michalkiewicz D, Makowski K et al. Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism. Clin. Endocrinol.74(4), 501–507 (2011).
   PubMed Web of Science ®Google Scholar
• Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol.32, 1454–1459 (1998).
   PubMed Web of Science ®Google Scholar
• Mariotti S, Barbesino G, Caturegli P et al. Complex alteration of thyroid function in healthy centenarians. J. Clin. Endocrinol. Metab.77, 1130–1134 (1993).
   PubMedGoogle Scholar
• Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr. Rev.16, 686–715 (1995).
   PubMed Web of Science ®Google Scholar
• Volzke H, Alte D, Kohlmann T et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid15, 279–285 (2005).
   PubMed Web of Science ®Google Scholar
• Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin. Endocrinol.70, 788–793 (2009).
   PubMed Web of Science ®Google Scholar
• Surks MI, Boucai L. Age- and race-based serum thyrotropin reference limits. J. Clin. Endocrinol. Metab.95, 496–502 (2010).
   PubMed Web of Science ®Google Scholar
• Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J. Clin. Endocrinol. Metab.95(6), 2715–2726 (2010).
   PubMed Web of Science ®Google Scholar
• Roberts LM, Pattison H, Roalfe A et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann. Intern. Med.145, 573–581 (2006).
   PubMed Web of Science ®Google Scholar
• Pearce EN, Yang Q, Benjamin EJ, Aragam J, Vasan RS. Thyroid function and left ventricular structure and function in the Framingham Heart Study. Thyroid20, 369–373 (2010).
   PubMedGoogle Scholar
• Dörr M, Ittermann T, Aumann N et al. Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up. Clin. Endocrinol.73, 821–826 (2010).
   PubMed Web of Science ®Google Scholar
• Rodondi N, Bauer DC, Cappola AR et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J. Am. Coll. Cardiol.52(14), 152–1159 (2008).
   Google Scholar
• Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med.331, 1249–1252 (1994).
   PubMed Web of Science ®Google Scholar
• Cappola AR, Fried LP, Arnold AM et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA295, 1033–1041 (2006).
   PubMed Web of Science ®Google Scholar
• Auer JA, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am. Heart J.142, 838–842 (2001).
   PubMedGoogle Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation98, 946–952 (1998).
   PubMed Web of Science ®Google Scholar
• Walsh JP, Bremner AP, Bulsara MK et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch. Intern. Med.165, 2467–2472 (2005).
   PubMedGoogle Scholar
• Boekholdt SM, Titan SM, Wiersinga WM et al. Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. Clin. Endocrinol.72, 404–410 (2010).
   PubMed Web of Science ®Google Scholar
• Ittermann T, Haring R, Sauer S et al. Decreased serum TSH levels are not associated with mortality in the adult northeast German population. Eur. J. Endocrinol.162(3), 579–585 (2009).
   PubMedGoogle Scholar
• Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet358, 861–865 (2001).
   PubMed Web of Science ®Google Scholar
• Sgarbi J, Matsumura L, Kasamatsu T, Ferreira S, Maciel R. Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5 year follow-up: the Japanese–Brazilian thyroid study. Eur. J. Endocrinol.162, 569–577 (2010).
   PubMedGoogle Scholar
• Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA292, 2591–2599 (2004).
   PubMed Web of Science ®Google Scholar
• Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J. Clin. Endocrinol. Metab.96(5), 1344–1351 (2011).
   PubMedGoogle Scholar
• Ochs N, Auer R, Bauer DC et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann. Intern. Med.148, 832–845 (2008).
   PubMed Web of Science ®Google Scholar
• Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur. J. Endocrinol.159(3), 329–341 (2008).
   PubMed Web of Science ®Google Scholar
• Iervasi G, Molinaro S, Landi P et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch. Intern. Med.167(14), 1526–1532 (2007).
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Weeke J, Mosekilde L. Fracture risk in patients treated for hyperthyroidism. Thyroid10, 341–348 (2000).
   PubMedGoogle Scholar
• Lee JS, Buzková P, Fink HA et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch. Intern. Med.170(21), 1876–1883 (2010).
   PubMedGoogle Scholar
• Dobert N, Hamscho N, Menzel C et al. Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta. Med. Aust.30, 130–133 (2003).
   PubMedGoogle Scholar
• Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin. Endocrinol.53, 733–737 (2000).
   PubMed Web of Science ®Google Scholar
• Dobert N, Hamscho N, Menzel C et al. Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta. Med. Austriaca30, 130–133 (2003).
   PubMedGoogle Scholar
• Tan ZS, Beiser A, Vasan RS et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch. Intern. Med.168, 1514–1520 (2008).
   PubMedGoogle Scholar
• van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology62, 1967–1971 (2004).
   PubMed Web of Science ®Google Scholar
• de Jong FJ, den Heijer T, Visser TJ et al. Thyroid hormones, dementia and atrophy of the medial temporal lobe. J. Clin. Endocrinol. Metab.91, 2569–2573 (2006).
   PubMedGoogle Scholar
• Faber J, Wiinberg N, Schifter S, Mehlsen J. Hemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur. J. Endocrinol.145, 391–396 (2001).
   PubMed Web of Science ®Google Scholar
• Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism. Effect of bone loss in postmenopausal women. Clin. Endocrinol.48, 285–290 (1998).
   PubMedGoogle Scholar
• Muddle AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin. Endocrinol.41, 421–424 (1994).
   PubMedGoogle Scholar
• Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab.87, 489–499 (2002).
   PubMed Web of Science ®Google Scholar
• Kratzsch J, Fiedler GM, Leichtle A et al. New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin. Chem.51, 1480–1486 (2005).
   PubMed Web of Science ®Google Scholar
• Baloch Z, Carayon P, Conte-Devolx B et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid13, 3–126 (2003).
   PubMed Web of Science ®Google Scholar
• Beckett G, MacKenzie F. Thyroid guidelines – are thyroid stimulating hormone assays fit for the purpose? Ann. Clin. Biochem.44, 203–208 (2007).
   PubMedGoogle Scholar
• Biondi B, Fazio S, Carella C et al. Control of adrenergic overactivity by β-blockade improves quality of life in patients receiving long term suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab.78, 1028–1033 (1994).
   PubMedGoogle Scholar
• Biondi B. Should we treat all subjects with subclinical thyroid disease the same way? Eur. J. Endocrinol.159(3), 343–345 (2008).
   PubMedGoogle Scholar
• McDermott MT, Woodmansee WW, Haugen BR, Smart A, Ridgway EC. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid13(12), 1133–1139 (2003).
   PubMed Web of Science ®Google Scholar
• Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin. Endocrinol.68(5), 814–820 (2008).
   PubMed Web of Science ®Google Scholar
• Bahn Chair RS, Burch HB, Cooper DS et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid21(6), 593–646 (2011).
   PubMed Web of Science ®Google Scholar
• Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J. Clin. Endocrinol. Metab.92, 2190–2196 (2007).
   PubMed Web of Science ®Google Scholar
• Walter MA, Briel M, Christ-Crain M et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ334(7592), 514 (2007).
   PubMed Web of Science ®Google Scholar